Patients with hepatocellular carcinoma may benefit from early PET/CT imaging after transarterial radioembolization to predict treatment response and survival, a new study found.
Early PET/CT imaging after transarterial radioembolization (TARE) for liver cancer could identify early who will respond to treatment and inform further treatment steps, a new study in France found.
The single-center retrospective study, published in American Journal of Roentgenology, evaluated the utility of PET/CT using fluorodeoxyglucose (FDG) or 18F-FCH (18F-fluorocholine) to predict six-month treatment response and overall survival (OS) after TARE in patients with hepatocellular carcinoma (HCC).
“Early posttreatment evaluation with PET/CT could help more reliably identify true nonresponders after TARE, which in turn could prompt early adapted therapeutic management,” the study authors, led by Edouard Reizine, MD, of Henri-Mondor University Hospital in Créteil, France, wrote.s
The study included 37 patients with HCC treated by TARE at Henri-Mondor University Hospital in Créteil, France, between February 2016 and August 2018. Those with portal vein tumor invasion or invasion or with unifocal or multifocal HCC not eligible for local therapies or transarterial chemoembolization (TACE) were included. Mean age was 67 and the majority (34) were men. FDG PET/CT and 18F-FCH PET/CT examinations were performed before treatment and 4 to 8 weeks after treatment.
Treatment response was assessed using modified response evaluation criteria in solid tumors (mRECIST).
“In patients with HCC treated by TARE, early posttreatment PET/CT response exhibited 100% sensitivity and 100% specificity for six-month mRECIST response, in comparison with 67% sensitivity and 100% specificity of one-month mRECIST response; early postteatment PET/CT response was also a significant independent predictor of OS (HR: 0.24, 95% CI: 0.08-0.76, P =.01),” the authors wrote.
On the PET/CT before treatment, 28 (76%) patients were FDG-positive, 15 (41%) FCH-positive 6 (16%) both FDG-positive and FCH-positive.
At one month after treatment, 12 of 28 (42.9%) FDG-positive HCCs exhibited early response by FDG PET/CT; and 7 of 15 (46.7%) FCH-positive HCCs exhibited early response by 18F-FCH PET/CT. At six months, 12 (52%) patients exhibited mRECIST response.
“Given the high percentage of HCCs that were FDG-positive, metabolic evaluation before and after TARE could be conducted by FDG alone in the large majority of patients,” the authors wrote. “Nonetheless, performing pretreatment PET/CT with both FDG and 18F-FCH helps detect additional HCCs not identified by conventional imaging, and the combination of the two tracers achieves very high sensitivity for HCC detection. Hence, imaging using both radiotracers may maximize the number of patients with HCC who benefit from metabolic evaluation.”
Limitations of the study include that it was retrospective, included only 37 participants out of 73 patients, and participants received a range of additional treatments after TARE. The authors also noted that 18F-FCH is not readily available.
The 5-year survival rate for HCC, which is the leading cause of liver cancer deaths,
Predicting how patients will respond to treatment has been a focus of providers. One recent study found that applying a deep convolutional neural network improved the ability to determine how a patient will respond to Y90-RE therapy.
Another study found that more frequent ultrasound screening in patients who are at high risk for developing HCC was associated with earlier HCC detection, decreased mortality, and improved quality of life.
Computed Tomography Insights on GI Bleeding: Nine Takeaways from New Consensus Recommendations
March 7th 2024In joint consensus recommendations issued from the Society of Abdominal Radiology and the American College of Gastroenterology, researchers discussed key pearls, benefits, and limitations of CT angiography for imaging of overt lower GI bleeding and CT enterography for detecting small bowel bleeding.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Deep Learning Bolster Image Quality with Low-Dose Lung CT?
March 4th 2024In comparison to standard-dose lung CT, the combination of deep learning image reconstruction with ultra-low-dose CT offered similar detection and characterization of pulmonary nodules at a nearly 93 percent reduction of radiation dosing, according to new research.
AMA Issues New CPT Code for AI Estimates of CCTA-Based Fractional Flow Reserve
February 26th 2024Clinicians can bill Category 1 CPT Code 75580 for adjunctive use of the artificial intelligence (AI)-powered Cleerly Ischemia software for fractional flow reserve estimates based on coronary computed tomography angiography (CCTA) scans.